Teva Pharmaceutical Industries Ltd reports $3.98 billion revenue for quarter ended March 31, 2026

ยท TEVA

Teva Pharmaceutical Industries Ltd reported revenue of $3.98 billion for the quarter ended March 31, 2026.

For the same period it posted net income of $369 million, or $0.31 per diluted share.

That is a net margin of 9.3%.

On Sanad's AAOIFI Standard 21 screen, Teva Pharmaceutical Industries Ltd is currently not compliant: interest-bearing debt is 34% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).

Is Teva Pharmaceutical Industries Ltd halal?
See the full AAOIFI screening of Teva Pharmaceutical Industries Ltd

Source: 10-Q filed with the U.S. Securities and Exchange Commission on April 29, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Teva Pharmaceutical Industries Ltd news